Trials / Conditions / Carbapenem-Resistant Enterobacteriaceae Infection

Carbapenem-Resistant Enterobacteriaceae Infection

23 registered clinical trials studyying Carbapenem-Resistant Enterobacteriaceae Infection — 9 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Microbiological and Clinical Characteristics of Severe Infections Caused by Carbapenem-Resistant Enterobactera NCT07160569	Fondazione Policlinico Universitario Agostino Gemelli IRCCS	—
Not Yet Recruiting	Precise Treatment of Ceftazidime-Avibactam in Patients With CRO Infections Under the Guidance of TDM and PPK M NCT06210542	Sichuan Provincial People's Hospital	—
Unknown	Fecal Microbiota Transplantation for Decolonization of Carbapenem-resistant Enterobacteriaceae NCT05981430	The University of Hong Kong	N/A
Recruiting	EaRly impAct theraPy With Ceftazidime-avibactam Via rapID Diagnostics NCT05979545	National University of Singapore	Phase 4
Completed	A Novel Approach to Antimicrobial Resistance: Machine Learning Predictions for Carbapenem-Resistant Klebsiella NCT05985057	Kocaeli University	—
Recruiting	Efficacy and Safety of Colistimethate Sodium for Injection in The Treatment of Carbapenem-Resistant Enterobact NCT06051513	Southeast University, China	N/A
Recruiting	Different Methods of Aerosolized Polymyxin B Inhalation for Treating Carbapenem-Resistant Gram-Negative Bacter NCT07086391	Fujian Medical University Union Hospital	—
Unknown	Drug Resistance Mechanism of Enterobacteriaceae and Its Strategies NCT05850871	Qianfoshan Hospital	N/A
Recruiting	Interventions to Decrease CRE Colonization and Transmission Between Hospitals, Households, Communities and Dom NCT05871476	Hanoi University of Public Health	N/A
Terminated	Ceftazidime-Avibactam Use in Critically Ill Patients With Carbapenem-Resistant Enterobacteriaceae Infections NCT05258851	King Faisal Specialist Hospital & Research Center	Phase 3
Terminated	Seven Versus 14 Days of Antibiotic Therapy for Multidrug-resistant Gram-negative Bacilli Infections NCT05210387	Hospital Moinhos de Vento	N/A
Unknown	Oral Capsule Faecal Microbiota Transplantation for CPE Decolonization NCT04746222	Tan Tock Seng Hospital	Phase 2 / Phase 3
Withdrawn	Imipenem/Cilastatin/Relebactam (IMI/REL) in Treatment of CRE Infections NCT04785924	Wake Forest University Health Sciences	Phase 4
Terminated	Best Available Therapy With or Without Meropenem for Bloodstream Infections by Enterobacterales With High Leve NCT04876430	Hospital de Clinicas de Porto Alegre	Phase 2 / Phase 3
Completed	Fecal Microbiota Transplantation for Carbapenem Resistant Enterobacteriaceae NCT04790565	Rambam Health Care Campus	Phase 2 / Phase 3
Recruiting	Risk Factors for Colonization or Infection With Carbapenem-Resistant Enterobacteriaceae in Children NCT04535661	Children's Hospital of Fudan University	—
Recruiting	Dynamics of Colonization and Infection by Multidrug-Resistant Pathogens in Immunocompromised and Critically Il NCT06258551	The Methodist Hospital Research Institute	—
Completed	Fecal Microbiota Transplantation for Carbapenem-resistant Enterobacteriaceae NCT04146337	Rambam Health Care Campus	Phase 2 / Phase 3
Unknown	Optimizing Antibiotic Dosing Regimens for the Treatment of Infection Caused by Carbapenem Resistant Enterobact NCT04516395	Phramongkutklao College of Medicine and Hospital	N/A
Completed	Impact of Ceftazidime / Avibactam Treatment vs Better Available Therapy on Mortality of Patients With Infectio NCT04167228	Maimónides Biomedical Research Institute of Córdoba	—
Recruiting	Safety and Efficacy of Fecal Microbiota Transplantation NCT04014413	Chinese University of Hong Kong	N/A
Completed	Community-associated Highly-Resistant Enterobacterales NCT03924934	University of North Carolina, Chapel Hill	—
Completed	The Effect of Fecal Microbiota Transplantation on the Decolonization of Multidrug-resistant Organisms NCT04583098	Chuncheon Sacred Heart Hospital	—